Active tuberculosis (TB) is one of the major opportunistic infections that may occur in solid organ transplant recipients. Diagnosis and treatment of latent and active TB are challenging in this population due to lack of randomized clinical trials. In this review, we discuss the clinical manifestations of TB, diagnosis of latent TB and treatment of both latent and active TB.
Epidemiology and clinical manifestations
The risk of active TB infection in patients receiving solid organ transplants is about 20 to 74 times higher than that in the general population, depending on the incidence of TB disease in the general population. The incidence of TB in developed countries in renal transplant recipients is 0.5 to 6.5% while this value is reported to be 15.4% in endemic areas (5-7).
The risk of TB incidence also relates to the type of transplantation and the treatment protocol. The recipients of lung transplantation have the highest risk of active TB.
In addition to the type of transplantation, anti-T cell antibodies, treatment of graft rejection, chronic renal failure, diabetes mellitus, hepatitis, chronic liver disease and old age all increase the risk of TB (8, 9) .
Most TB cases occur during the first 6 months after Various manifestations of TB are not considered as the primary diagnosis in one-third of patients; 3% to 5% of patients are diagnosed after death (13) (14) . In addition, the possibility of poorer outcome in this group of patients is higher. Mortality in these patients is approximately 57% to 80% and is directly related to TB. Another important point is the significant interaction of anti-TB and immunosuppressant drugs that cause rejection in one-third of patients (13) (14) (15) (16) .
Diagnosis and treatment of latent tuberculosis
The diagnosis of latent TB infection is based on 2 laboratory tests, which measure the immune response to mycobacterial antigens including TST and interferon- release assay (IGRA).
IGRA tests are done in two ways. Latent TB is treated by using isoniazid for 9 months. Usage of rifampin is an alternative treatment. However, rifampin has extensive interactions with immunosuppressive drugs
and cannot be used after transplantation. The use of rifampin and pyrazinamide is not recommended due to the high risk of hepatotoxicity (1, 4, 6) .
Prevention efforts for TB should be started before transplantation. In some patients, such as those undergoing kidney transplantation, initiation of treatment before transplantation should be considered. However, in some cases, particularly in emergency situations, treatment in pre-transplant period is not feasible so it can be completed after transplantation.
In some types of transplants, including liver transplantation secondary to advanced liver failure, prevention before transplantation is not possible and prophylaxis can be done after liver transplantation (17) (18) (19) (20) (21) (22) .
Active tuberculosis treatment
Treatment of active TB in transplant patients must be started as soon as the diagnosis is made. Treatment in these patients has two main challenges: Pre-transplant screening with both PPD and IGRA tests may increase sensitivity for detection of latent TB.
Treatment of TB with rifampicin-containing regimens for longer duration is recommended for severe cases.
Usage of rifabutin has lower risk of drug interaction.
